TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28968031

Group type: EXPERIMENTAL
Intervention: Standard medical therapy + ozone therapy (subgroup 1a: intravenous ozonized physiological solution, n=28)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Standard medical therapy + ozone therapy (subgroup 1b: major ozonized autohemotherapy, n=29)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Comprehensive treatment including gravitational therapy + medical ozone (subgroup 2a: standard medical therapy + ozonized physiological solution + gravitational therapy, n=31)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Comprehensive treatment including gravitational therapy + medical ozone (subgroup 2b: standard medical therapy + major ozonized autohemotherapy + gravitational therapy, n=31)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Standard medical therapy only (control group, n=20)
Number of subjects: 139
Study: 26269002

Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 mg or 30 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (no pioglitazone)
Number of subjects: 120
Study: 23466754

Group type: EXPERIMENTAL
Intervention: Motivational interviewing plus incentives (MI+)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional care (CC)
Number of subjects: 0
Study: 21070297

Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246

Group type: COMPARATOR
Intervention: Sibutramine and Placebo
Number of subjects: 246
Study: 19855170

Group type: EXPERIMENTAL
Intervention: HPV 6/11/16/18 vaccine
Number of subjects: 2617

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2617
Study: 16267842

Group type: EXPERIMENTAL
Intervention: Piribedil 150 mg/day
Number of subjects: 425

Group type: COMPARATOR
Intervention: Bromocriptine 25 mg/day
Number of subjects: 425
Study: 14720615

Group type: EXPERIMENTAL
Intervention: 3 mg drospirenone/30 microg ethinylestradiol
Number of subjects: 0

Group type: COMPARATOR
Intervention: 150 microg levonogestrel/30 microg ethinylestradiol
Number of subjects: 0
Study: 10866253

Group type: EXPERIMENTAL
Intervention: First Access for Shock and Trauma (FAST)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Bone Injection Gun
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: SurFast
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Jamshidi needle
Number of subjects: 31
Study: 9114758

Group type: EXPERIMENTAL
Intervention: Mibefradil 50 mg
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study: 1423365

Group type: EXPERIMENTAL
Intervention: K-strophanthidin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 4045435

Group type: EXPERIMENTAL
Intervention: 5-micrograms recombinant hepatitis B vaccine
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 10-micrograms recombinant hepatitis B vaccine
Number of subjects: 110

Group type: COMPARATOR
Intervention: plasma-derived hepatitis B vaccine (5-micrograms)
Number of subjects: 110

Group type: COMPARATOR
Intervention: plasma-derived hepatitis B vaccine (10-micrograms)
Number of subjects: 110
Study: 2956867

Group type: EXPERIMENTAL
Intervention: Intravenous enoximone at a maximum cumulative dose of 3.0 mg/kg
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Intravenous enoximone at a maximum cumulative dose of 10.5 mg/kg
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Intravenous enoximone
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Adverse effects of intravenous enoximone
Number of subjects: 118
Study: 29288102

Group type: EXPERIMENTAL
Intervention: Picosecond alexandrite laser (PSAL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Q-switched alexandrite laser (QSAL)
Number of subjects: 30
Study: 27979912

Group type: EXPERIMENTAL
Intervention: Incision in the right atrium joining the lateral tunnel suture line and the tricuspid valve annulus
Number of subjects: 134

Group type: COMPARATOR
Intervention: No incision (Control)
Number of subjects: 134
Study: 25768800

Group type: EXPERIMENTAL
Intervention: Individualized homeopathic treatment
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 23174090

Group type: EXPERIMENTAL
Intervention: D-cycloserine (1000 mg/d)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 19909980

Group type: EXPERIMENTAL
Intervention: LY2216684
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 269

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study: 18403765

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting with emboli-protection device
Number of subjects: 334

Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 334
Study: 16649875

Group type: EXPERIMENTAL
Intervention: Abstinence-based vouchers
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of abstinence-based vouchers and cognitive-behavioral therapy
Number of subjects: 90
Study: 12732601

Group type: EXPERIMENTAL
Intervention: Acolysis (therapeutic ultrasound)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Abciximab
Number of subjects: 181
Study: 10819856

Group type: EXPERIMENTAL
Intervention: Atosiban (30 microg/min continuous subcutaneous infusion)
Number of subjects: 513

Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 513

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 513

Group type: COMPARATOR
Intervention: Atosiban and Placebo
Number of subjects: 513
Study: 8625548

Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (IVIG)
Number of subjects: 373
Study: 1340743

Group type: EXPERIMENTAL
Intervention: Captopril + Hydrochlorothiazide (C + HCTZ)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Chlorthalidone (CT)
Number of subjects: 55
Study: 6437467

Group type: EXPERIMENTAL
Intervention: 50 mg SSHA
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: 37.5 mg SSHA
Number of subjects: 440

Group type: COMPARATOR
Intervention: 5000 units sodium heparin
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 440
Study: 31427224

Group type: EXPERIMENTAL
Intervention: Dissonance-based group intervention (4 sessions, 2-3 months post-surgery)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Regular care (control group)
Number of subjects: 259
Study: 30178515

Group type: EXPERIMENTAL
Intervention: Genotype-guided tacrolimus dosing
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard tacrolimus dosing
Number of subjects: 53
Study: 27553581

Group type: EXPERIMENTAL
Intervention: Landiolol infusion (5 μg/kg/min during general anesthesia)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo control (no landiolol)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Landiolol infusion
Number of subjects: 50
Study: 24554512

Group type: EXPERIMENTAL
Intervention: Oral contraceptive pill (OC) containing ethynyloestradiol and cyproterone acetate (EE‐CPA) for 4 months
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Metformin (MET) 850 mg bid for 4 months
Number of subjects: 42

Group type: COMPARATOR
Intervention: Metformin (MET) or EE‐CPA for 4 months
Number of subjects: 42
Study: 22936190

Group type: EXPERIMENTAL
Intervention: Communication robot
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control robot
Number of subjects: 34
Study: 20937655

Group type: EXPERIMENTAL
Intervention: Essential Newborn Care (ENC) training
Number of subjects: 1096

Group type: EXPERIMENTAL
Intervention: Neonatal Resuscitation Program (NRP) training
Number of subjects: 1096

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 1096
Study: 18664053

Group type: EXPERIMENTAL
Intervention: Vulvodynia (vestibulodynia and generalized vulvodynia)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Candida vulvovaginitis
Number of subjects: 246
Study: 16038682

Group type: EXPERIMENTAL
Intervention: Voxel-based morphometry (VBM)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Volumetric analyses of the ACC
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Probabilistic maps of the labels of the pregenual ACC
Number of subjects: 14

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 14
Study: 11775762

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty and stent placement
Number of subjects: 10000000

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 10000000

Group type: COMPARATOR
Intervention: Surgical bypass
Number of subjects: 10000000
Study: 15321222

Group type: EXPERIMENTAL
Intervention: 1 L Ringer's solution preload administered over 10 min before spinal anaesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: No preload
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups received prophylactic infusion of ephedrine (60 mg in Ringer's solution 1000 ml) after spinal anaesthesia
Number of subjects: 40
Study: 7923256

Group type: EXPERIMENTAL
Intervention: 2 mg/day terazosin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5 mg/day terazosin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg/day terazosin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3136963

Group type: EXPERIMENTAL
Intervention: Indomethacin 25 mg three times daily for the first six postoperative weeks
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 193
Study: 31249332

Group type: EXPERIMENTAL
Intervention: Kinect-based exergaming (EXER group)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Combined exercise (CE group)
Number of subjects: 52
Study: 27620962

Group type: EXPERIMENTAL
Intervention: Perceived neighborhood crime safety
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Perceived neighborhood crime safety in low fear of falling group
Number of subjects: 238
Study: 26445075

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 610

Group type: COMPARATOR
Intervention: Bevacizumab 1.25 mg
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Continuous treatment regimen
Number of subjects: 610

Group type: COMPARATOR
Intervention: Discontinuous treatment regimen
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Continuous treatment
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Continuous ranibizumab
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Continuous bevacizumab
Number of subjects: 610
Study: 22995972

Group type: EXPERIMENTAL
Intervention: JNJ-37822681 10 mg bid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: JNJ-37822681 20 mg bid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: JNJ-37822681 30 mg bid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 0
Study: 21296118

Group type: EXPERIMENTAL
Intervention: 9-valent pneumococcal and meningococcal serogroup C conjugate vaccine (9vPnC‐MnCC)
Number of subjects: 467

Group type: COMPARATOR
Intervention: 9-valent pneumococcal conjugate vaccine (9vPnC)
Number of subjects: 467
Study: 19293355

Group type: EXPERIMENTAL
Intervention: Beraprost sodium, 120 microg daily for 8 weeks
Number of subjects: 100
Study: 17852714

Group type: EXPERIMENTAL
Intervention: Vocal Hygiene Training (VH)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Vocal Function Exercises (VFE)
Number of subjects: 37

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 37
Study: 15153174

Group type: EXPERIMENTAL
Intervention: 15 mg lansoprazole orally disintegrating tablet dispersed in water and administered orally via syringe
Number of subjects: 40

Group type: COMPARATOR
Intervention: 15 mg intact lansoprazole orally disintegrating tablet administered directly onto the tongue without water
Number of subjects: 40
Study: 11557646

Group type: EXPERIMENTAL
Intervention: leflunomide 20 mg/day
Number of subjects: 358

Group type: COMPARATOR
Intervention: sulfasalazine 2 g/day
Number of subjects: 358
Study: 9710891

Group type: EXPERIMENTAL
Intervention: IL-10
Number of subjects: 0
Study: 7835329

Group type: EXPERIMENTAL
Intervention: Breakfast cereal with 43 g sucrose
Number of subjects: 12

Group type: COMPARATOR
Intervention: Breakfast cereal with 0 g sucrose (non-sweetened)
Number of subjects: 12
Study: 3050005

Group type: EXPERIMENTAL
Intervention: Sucralfate suspension
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 29797909

Group type: EXPERIMENTAL
Intervention: Acupuncture at Feishu (BL 13), Xinshu (BL 15), Pishu (BL 20), Ganshu (BL 18), Shenshu (BL 23), Geshu (BL 17), and Shenmen (HT 7) once a day, with a 2-day interval after every 5 days of treatment for 3 weeks.
Number of subjects: 128

Group type: COMPARATOR
Intervention: Alprazolam (0.4 mg or 0.8 mg) orally before sleep for 3 weeks.
Number of subjects: 128
Study: 27816057

Group type: EXPERIMENTAL
Intervention: Complex intervention designed to support screening and brief intervention for problem alcohol use
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 81
Study: 26517587

Group type: EXPERIMENTAL
Intervention: Incentive-based health interventions for weight loss
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Incentive-based health interventions for diabetes self-monitoring
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Change in PAM score and SoC among participants in the intervention groups
Number of subjects: 207
Study: 23506383

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test, HbA1c, biochemical and anthropometric data
Number of subjects: 193
Study: 21685640

Group type: EXPERIMENTAL
Intervention: Virtual Reality Based Exposure Therapy (VRBET)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Virtual Reality Based Exposure Therapy (VRBET) combined with cognitive therapy
Number of subjects: 10
Study: 19533177

Group type: EXPERIMENTAL
Intervention: Anterior lean traction
Number of subjects: 32

Group type: COMPARATOR
Intervention: Axial traction
Number of subjects: 32
Study: 16394961

Group type: EXPERIMENTAL
Intervention: Psychological empowerment intervention (PEI)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Traditional strength training (TST)
Number of subjects: 38
Study: 15612966

Group type: EXPERIMENTAL
Intervention: Budesonide once daily (up to 800 microg per day)
Number of subjects: 1922

Group type: COMPARATOR
Intervention: Budesonide twice daily (up to 800 microg per day)
Number of subjects: 1922
Study: 11312481

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (7.5%)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Normal saline (0.9%)
Number of subjects: 48

Group type: COMPARATOR
Intervention: 6% hydroxyethyl starch (HES)
Number of subjects: 48
Study: 7717370

Group type: EXPERIMENTAL
Intervention: Low dose 13‐Cis‐Retinoic Acid (80 mg daily for 6 months)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: High dose 13‐Cis‐Retinoic Acid (200 mg po daily for 3 months)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Danazol (800 mg po daily for 3 months)
Number of subjects: 46
Study: 2235346

Group type: EXPERIMENTAL
Intervention: Z-100 (Z group)
Number of subjects: 178

Group type: COMPARATOR
Intervention: L-cysteine (L group)
Number of subjects: 178
Study: 631413

Group type: EXPERIMENTAL
Intervention: Temazepam (Euhypnos)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Chlormethiazole syrup
Number of subjects: 2
Study: 31869281

Group type: EXPERIMENTAL
Intervention: Group-randomized trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individually randomized group treatment trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stepped-wedge group-randomized trial
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional randomized controlled trial
Number of subjects: 0
Study: 31135603

Group type: EXPERIMENTAL
Intervention: Mindfulness-based group therapy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study: 28611324

Group type: EXPERIMENTAL
Intervention: Mango leaf mouthwash
Number of subjects: 20

Group type: COMPARATOR
Intervention: Chlorhexidine
Number of subjects: 20
Study: 26482865

Group type: EXPERIMENTAL
Intervention: Vitamin C (2 × 500 mg/day) and E (400 IU/day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 24486352

Group type: EXPERIMENTAL
Intervention: Inactivated quadrivalent influenza vaccine (QIV)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Inactivated trivalent influenza vaccine (TIV)
Number of subjects: 100
Study: 22180452

Group type: EXPERIMENTAL
Intervention: Prednisone 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prednisone 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prednisone 60 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prednisone (all doses)
Number of subjects: 0
Study: 19566585

Group type: EXPERIMENTAL
Intervention: SLIT with a glycerinated mixture of birch, hazel and alder with a cumulative weekly dose of 24,000 SQ-U
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SLIT with a glycerinated mixture of birch, hazel and alder with a cumulative weekly dose of 200,000 SQ-U
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 17599433

Group type: EXPERIMENTAL
Intervention: Eptifibatide in the ER
Number of subjects: 281

Group type: COMPARATOR
Intervention: Not treated with eptifibatide in the ER (Control)
Number of subjects: 281
Study: 16253583

Group type: EXPERIMENTAL
Intervention: 40 mg of pravastatin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 80 mg of atorvastatin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both atorvastatin and pravastatin
Number of subjects: 50
Study: 12010337

Group type: EXPERIMENTAL
Intervention: Suction blister technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thin split-thickness graft technique
Number of subjects: 0
Study: 10572352

Group type: EXPERIMENTAL
Intervention: Mirtazapine for 28 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline for 28 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirtazapine for six months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluoxetine for six months
Number of subjects: 0
Study: 8951782

Group type: EXPERIMENTAL
Intervention: Aggressive cytoreductive treatments with chemotherapeutic agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phlebotomy and preventive antiplatelet therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multi-country, collaborative RCTs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Core data and practices from multicenter trials
Number of subjects: 0
Study: 1829574

Group type: EXPERIMENTAL
Intervention: Intravenous bolus of alteplase (70 mg or 80 mg if body weight >= 90 kg)
Number of subjects: 60
Study: 6667627

Group type: EXPERIMENTAL
Intervention: 8 mg slow-release salbutamol tablet
Number of subjects: 9

Group type: COMPARATOR
Intervention: 1 standard 4 mg tablet
Number of subjects: 9

Group type: COMPARATOR
Intervention: 2 standard 4 mg tablets
Number of subjects: 9
Study: 31752952

Group type: EXPERIMENTAL
Intervention: Inspiratory flow of 400, 800, and 1200 ml/s
Number of subjects: 10

Group type: COMPARATOR
Intervention: Higher PEEP levels (5 and 15 cmH2O)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Higher inspiratory flow
Number of subjects: 10
Study: 29797588

Group type: EXPERIMENTAL
Intervention: Single-player exergame condition (n=30)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Multi-player exergame condition (n=39)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 69
Study: 26867588

Group type: EXPERIMENTAL
Intervention: SMS-text based weight maintenance messages and a single maintenance support phone call over 12 weeks
Number of subjects: 380

Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 380
Study: 25219353

Group type: EXPERIMENTAL
Intervention: Rufinamide
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 22882107

Group type: EXPERIMENTAL
Intervention: Physical educators' expectations for overweight students
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Physical educators' performance expectations for overweight students
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Physical educators' attributions for overweight students
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Physical educators' attitudes toward overweight students
Number of subjects: 162
Study: 19603316

Group type: EXPERIMENTAL
Intervention: Intramuscular syntometrine
Number of subjects: 686

Group type: COMPARATOR
Intervention: Intravenous syntocinon
Number of subjects: 686
Study: 17264952

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 436
Study: 15041401

Group type: EXPERIMENTAL
Intervention: EC-MPS, 720 mg b.i.d.
Number of subjects: 322

Group type: COMPARATOR
Intervention: MMF, 1000 mg b.i.d.
Number of subjects: 322
Study: 11583477

Group type: EXPERIMENTAL
Intervention: Thalidomide at a dose of 200 mg daily for 4 weeks
Number of subjects: 20
Study: 9845448

Group type: EXPERIMENTAL
Intervention: Calcar screw placement
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional screw placement
Number of subjects: 20
Study: 10933340

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (2, 4 and 8 mg/70 kg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25, 0.5 and 1 mg/70 kg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (highest dose)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (all doses)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Triazolam (all doses)
Number of subjects: 14
Study: 2715471

Group type: EXPERIMENTAL
Intervention: Sugarless gum (four pieces per day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (no vigorous mastication)
Number of subjects: 11
Study: 577876

Group type: EXPERIMENTAL
Intervention: Imipramine (100 mg orally)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lofepramine (140 mg orally)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lofepramine
Number of subjects: 24